Search results
Results from the WOW.Com Content Network
The combination of dabrafenib and trametinib was approved for NHS use for youngsters with brain tumours in April. However, Alexander has been accessing the medication privately at a cost of about ...
Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4] [5] and glioma. [ 6 ] [ 7 ] It is a MEK inhibitor drug with anti-cancer activity. [ 8 ]
Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.
A phase III trial (vs dacarbazine) in patients with previously untreated metastatic melanoma showed an improved rates of overall and progression-free survival. [18] In June 2011, positive results were reported from the phase III BRIM3 BRAF-mutation melanoma study. [19] The BRIM3 trial reported good updated results in 2012. [20]
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
Share Your Story. To share a story about your or a loved one’s experience with drug treatment, write to treatmentstories@huffingtonpost.com or leave a voice mail at 860-348-3376. Please include your phone number.
The major efficacy measure was progression-free survival (PFS) using RECIST 1.1 response criteria and assessed by blinded independent central review. [6] The median PFS was 14.9 months for participants receiving binimetinib plus encorafenib, and 7.3 months for the vemurafenib monotherapy arm (hazard ratio 0.54, 95% CI: 0.41, 0.71, p<0.0001). [6]